Company intelligence / Profile preview

Al Hammadi

Riyadh, Riyadh, Saudi Arabia

Ownership: Private
Employees: ~3245
Development stage: Other

Overview

Al Hammadi operates major hospital facilities, is expanding into pharmaceutical manufacturing via its Sudair Pharmaceutical Company stake (oncology, insulin, and respiratory), and is a key distributor of vaccines. Its cancer drugs business is commercially active since 2021, with insulin and respiratory drugs in the pipeline for 2025.

Therapeutic areas: OncologyInfectious DiseasesEndocrinologyPulmonology
Modalities: Small moleculeBiologic
Industry: Non-Academic Healthcare

Beyond the preview

Go deeper on Al Hammadi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Al Hammadi.

Explore the full profile